This year’s RELX SDG Inspiration Day will bring together global AI leaders, corporate representatives, investors, government, and NGOs to explore issues, gain practical insights and be inspired to take action in support of the Global Goals. Elsevier is proud to share this special collection of articles and chapters in celebration of this event.
Elsevier,
Remington and Klein's Infectious Diseases of the Fetus and Newborn Infant (Ninth Edition), 2025, Pages 728-744.e4
This content aligns with Goal 3: Good Health. Public health programs at the governmental level are in need for prevention of the maternal-fetal transmission of these viruses and access to available antiviral therapies.
This study developed four deep learning models to identify potential Alzheimer's disease treatments from traditional Chinese medicine, specifically the Kaixinsan formula. The models successfully predicted compounds that showed significant anti-Alzheimer's activities in various experimental validations.
This article supports SDG 3 by showing that using an interactive mHealth application can reduce dementia risk factors in populations who are underserved and at increased risk.
This article looks at complications that arise from combinations of Alzheimers and osteoporosis in mouse models
This investigation aimed to understand preclinical biomarker and genetic Alzheimer’s disease research participation in underrepresented groups to facilitate greater diversity in future biomarker research and clinical trials.
This study finds that impaired cellular immune dysfunction in AD patients was significantly correlated with abnormal MRS, and neuroimmune dysfunction may contribute to the pathogenesis of AD and alter the metabolism of neurotransmitters such as aspartic acid and MI in the brains of AD patients.
This study identified key biochemical pathways and protein changes in the Alzheimer's disease (AD) human hippocampus, revealing increased expression of proteins VGF, GFAP, HSPB1, and APP, with UBC being most centrally involved, and highlighted the roles of four hub proteins (CD44, APP, ITGB2, APOE) linked to amyloid plaques and two (RPL24, RPS23) to neurofibrillary tangles, along with the impact of modified proteins on immune activation and synaptic disruption, uncovering potential therapeutic targets involving specific proteins, microRNAs, and transcription factors.
Recent research on Alzheimer's disease (AD) suggests that microglia, immune cells in the brain, may play a beneficial role in early disease stages but become harmful in later stages due to various spatial, temporal, and transcriptional factors. Understanding the phenotypic heterogeneity and multiple states of microglia could lead to advancements in personalized medicine and improved treatment outcomes for AD patients.
This article summarizes current biomarkers, available treatments, and future therapeutic approaches for Alzheimer's disease, discussing drug targets like Amyloid β, Tau Protein, and various other mechanisms. Additionally, it highlights the historical use of Estradiol, outcomes of trials with antioxidants and omega-3 fatty acids, and ongoing clinical trials, providing a comprehensive overview of the evolving landscape in AD research and treatment.
